Loading clinical trials...

Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma | Clinical Trials | Clareo Health

TERMINATEDPHASE2

Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma

A Phase II Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma

NCT03120676•Memorial Sloan Kettering Cancer Center

Summary

This is a study with the purpose of studying the safety and efficacy of the study drug Atezolizumab in patients with relapsed or refractory Hodgkin lymphoma (HL). Atezolizumab could shrink cancer but it could also cause side effects. This study will also test any good and bad effects the study drug. Other aims include studying biomarkers that will help researchers understand how the drug works.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Signed Informed Consent Form (ICF)
•Ability and willingness to comply with the requirements of the study protocol
•Age ≥ 18 years
•Patient has histologically confirmed diagnosis of Hodgkin lymphoma
•Patients must have received at least 2 prior regimens and have received or be deemed ineligible for autologous stem cell transplant, and must have received prior brentuximab vedotin.
•Patients who received prior anti-PD-1 therapy are eligible for cohort 1 only and patients who have not received prior anti-PD-1 therapy are eligible for cohort 2 only.
•Patient has at least one measurable nodal lesion (≥ 2 cm) according to RECIL Criteria
•Adequate hematologic and end organ function, defined by the following laboratory results obtained within 14 days prior to the first study treatment (Cycle 1, Day 1):
•* ANC ≥ 1500 cells/µL
•* WBC counts \> 2500/µL
+13 more criteria

Exclusion Criteria

•Patients who have undergone prior allogeneic transplant are excluded only if they remain on any immunosuppression or have signs or symptoms of clinical graft-versus-host disease
•Any approved anticancer therapy, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to initiation of study treatment.
•Herbal therapy (including herbal therapy intended as anticancer therapy) \< 1 week prior to Cycle 1, Day 1
•AEs from prior anticancer therapy that have not resolved to Grade ≤ 1 except for alopecia
•Known clinically significant liver disease
•Active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver; and inherited liver disease
•Pregnancy, lactation, or breastfeeding
•Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
•Inability to comply with study and follow-up procedures
•History or risk of autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Bell's palsy, Guillain-Barré syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis
+26 more criteria

Locations (6)

Memorial Sloan Kettering Basking Ridge

Basking Ridge, New Jersey, United States

Memorial Sloan Kettering Monmouth

Middletown, New Jersey, United States

Memorial Sloan Kettering Commack

Commack, New York, United States

Memorial Sloan Kettering Westchester

Harrison, New York, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Memorial Sloan Kettering Rockville Centre

Rockville Centre, New York, United States

Key Dates

Start Date

April 14, 2017

Primary Completion Date

November 12, 2018

Completion Date

November 12, 2018

Last Updated

November 14, 2019

Enrollment

ACTUAL participants

Conditions

Hodgkin Lymphoma

Interventions

Atezolizumab

DRUG

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

NCT05529069

Mantle Cell LymphomaNon Hodgkin Lymphoma+1 more

View study

RECRUITINGPHASE1

A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)

NCT06189391

Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 14, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma

Inclusion Criteria

Exclusion Criteria

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma